CiVi Biopharma
Recent Finacing
Equity
Recent Raise
$40M
CiVi Biopharma is a San Francisco–based biopharmaceutical company with a Danish subsidiary developing LNA/GalNAc-targeted PCSK9 RNA therapies for cardiometabolic diseases, advancing preclinical and early phase I programs.
Highlights
Focus Areas
Biotechnology
Clinical Trials
Pharmaceutical
Recent Investors
Financials
$40M
Total Raised
1
Funding round
1
Investor